A, Schematic of chemical synthetic vulnerability screens. Clinical related drugs (n=21) were combined with BI2536 to treat BEAS-2B-KRAS cells harboring a KRASG12V allele. Cell viability was determined 72 h post-treatment, with combination index (CI) calculated by CalcuSyn software: CI＞1, antagonism; 1＞CI＞0.8, synergy; CI＜0.8, strong synergy Drug combinations leading to strong synergy (CI＜1) in BEAS-2B-KRAS were further tested in KRAS wild-type BEAS-2B cells, where CI＜1 indicates toxicity and CI＞1 safety. 